Tegaserod treatment for dysmotility-like functional dyspepsia: Results of two randomized, controlled trials

American Journal of Gastroenterology

Volumn 103, Issue 8, 2008, Pages 1906-1919

  Vakil, Nimish ^a,h   Laine, Loren ^b   Talley, Nicholas J ^c   Zakko, Salam F ^d   Tack, Jan ^e   Chey, William D ^f   Kralstein, Jeffrey ^g   Earnest, David L ^g   Ligozio, Gregory ^g   Cohard Radice, Marielle ^g  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Mayo Clinic   (United States)

^d Connecticut Gastroenterology Institute ^*  (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h MARQUETTE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEROTONIN 4 AGONIST; TEGASEROD;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; INTESTINAL DYSMOTILITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL CHEST PAIN; NAUSEA; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SATIETY; SCORING SYSTEM; SYMPTOM; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DYSPEPSIA; ESOPHAGEAL MOTILITY DISORDERS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; SEROTONIN AGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49349102447     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01953.x     Document Type: Article

References (48)

1. El-Serag HB, Talley NJ. Systemic review: The prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004 19 : 643 54.
2. Drossman DA, Corazziari E, Talley NJ, et al. Rome II: The functional gastrointestinal disorders. McLean, VA : Degnon Associates, 2000.
3. Thomson ABR, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003 17 : 1481 91.
4. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006 130 : 1466 79.
5. El-Serag HB, Talley NJ. Systematic review: Health-related quality of life in functional dyspepsia. Aliment Pharmacol Ther 2003 18 : 387 93.
6. Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995 40 : 584 9.
7. Choung RS, Talley NJ. Novel mechanisms in functional dyspepsia. World J Gastroenterol 2006 12 : 673 7.
8. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006 55 : 1681 91.
9. Quigley E. Review article: Gastric emptying in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004 20 : 56 60.
10. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004 127 : 1239 55.
11. Sarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003 98 : 783 8.
12. Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. Gastroenterology 2005 129 : 1756 80.
13. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005 100 : 2324 37.
14. Peura DA, Kovacs TO, Metz DC, et al. Lansoprazole in the treatment of functional dyspepsia: Two double-blind, randomized, placebo-controlled trials. Am J Med 2004 116 : 740 8.
15. Wong WM, Wong BC, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002 51 : 502 6.
16. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998 12 : 1055 65.
17. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004 2 : 796 805.
18. Kamm MA, Müller-Lissner S, Talley NJ, et al. Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005 100 : 362 72.
19. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 66.
20. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002 16 : 1877 88.
21. Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C). Gut 2005 54 : 1707 13.
22. Tougas G, Cheng Y, Luo D, et al. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology 2003 124 (Suppl 2 A54.
23. Van Der Voort IR, Schmidtmann M, Fach K, et al. Tegaserod improves gastric emptying and alters myocardial activity in dyspeptic patients. Gastroenterology 2004 126 (Suppl 2 A643.
24. Talley N, Tack J, d'Elia T, et al. Tegaserod, a partial 5-HT4 agonist, in functional dyspepsia patients with normal gastric emptying: A randomized, double-blind, placebo-controlled trial. Gut 2002 51 : A193.
25. Nasra I, Ashok A, Summers R, et al. Effect of tegaserod on antroduodenal and jejunal motility. Gastroenterology 2006 130 (Suppl 2 A743.
26. Thumshirn M, Fruehauf H, Stutz B, et al. Effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia and healthy controls. Gastroenterology 2005 128 (Suppl 2 A469.
27. Tack J, Vos R, Tougas G, et al. Effect of tegaserod, a 5-HT4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastroenterology 2005 128 (Suppl 2 A94.
28. Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003 17 : 577 85.
29. Sabate J, Bouhassira D, Poupardin C, et al. Antinociceptive effect of tegaserod in female IBS constipated patients. Gastroenterology 2005 128 (Suppl 2 A 468.
30. Tack J, Delia T, Ligozio G, et al. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) with normal gastric emptying (NGE). Gastroenterology 2002 122 (Suppl 2 A 20.
31. Vakil N, Van Zanten SV, Chang L, et al. Comprehension and awareness of symptoms in women with dyspepsia. Aliment Pharmacol Ther 2005 22 : 1147 55.
32. Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: Responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther 2001 15 : 207 16.
33. Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: A United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 1999 94 : 2390 7.
34. O'Donnell LJD, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990 300 : 439 40.
35. Sturm A, Holtmann G, Goebell H, et al. Prokinetics in patients with gastroparesis: A systematic analysis. Digestion 1999 60 : 422 7.
36. Bolling-Sternevald E, Lauritsen K, Talley NJ, et al. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 2003 18 : 117 24.
37. Talley NJ. American Gastroenterological Association medical position statement: Evaluation of dyspepsia. Gastroenterology 2005 129 : 1753 5.
38. Talley NJ, Vakil N, Ballard ED, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999 341 : 1106 11.
39. Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up. The optimal regimen cures helicobacter induced dyspepsia (ORCHID) study group. BMJ 1999 318 : 833 7.
40. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: The BOND, OPERA, PILOT, and ENCORE studies. Gut 2002 50 : iv36-41.
41. Van PB, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006 3 : CD002095.
42. Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006 CD001960.
43. Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: A randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000 14 : 1653 61.
44. Choung RS, Talley NJ, Peterson J, et al. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007 19 : 180 7.
45. Akyuz F, Mimidis K, Mikolai H, et al. Influence of itopride and domperidone on gastric tone and on the perception of gastric distention in healthy subjects. Gastroenterology 2007 132 (Suppl 2 A688.
46. Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006 354 : 832 40.
47. Talley NJ, Tack J, Ptak T, et al. Efficacy and safety of itopride in functional dyspepsia: Results of two phase III multicentre, randomized, double-blind, placebo-controlled trials. Gastroenterology 2007 132 (Suppl 2 A93.
48. Food and Drug Administration. Patient-reported outcome measures: Use in medical product development to support labeling claims 2007. Available at : http://www. fda.gov/cber/gdlns/prolbl.htm. Accessed August 12, 2007.